RadioLigand Therapy with [¹⁷⁷Lu]Lu-PSMA-617 for Salivary Gland Cancers: Literature Review and First Compassionate Use in France

• Main Authors: Marie Terroir (Author), Chloé Lamesa (Author), Mehdi Krim (Author), Lavinia Vija (Author), Jean-Sébastien Texier (Author), Thibaut Cassou-Mounat (Author), Jean-Pierre Delord (Author), Delphine Vallot (Author), Frédéric Courbon (Author)
• Format: Book
• Published: MDPI AG, 2023-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary

Salivary gland cancers are rare tumors comprising a large group of heterogeneous tumors with variable prognosis. Their therapeutic management at a metastatic stage is challenging due to the lack of therapeutic lines and the toxicity of treatments. [¹⁷⁷Lu]Lu-PSMA-617 (prostate-specific membrane antigen) is a vectored radioligand therapy (RLT) initially developed to treat castration-resistant metastatic prostate cancer with encouraging results in terms of efficacy and toxicity. Many malignant cells could be treated with [¹⁷⁷Lu]Lu-PSMA-617 as long as they express PSMA as a consequence of androgenic pathway activation. RLT may be used when anti-androgen hormonal treatment has failed, particularly in prostate cancer. [¹⁷⁷Lu]Lu-PSMA-617 has been proposed in certain salivary gland cancers, though the expression of PSMA is demonstrated by a significant uptake using [⁶⁸Ga]Ga-PSMA-11 PET scan. This theranostic approach could be a new therapeutic option, warranting prospective investigation in a larger cohort. We review the literature on this subject and offer a clinical illustration of compassionate use in France as a perspective for administering [¹⁷⁷Lu]Lu-PSMA-617 in salivary gland cancer.

Item Description

10.3390/ph16050754
1424-8247